{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:45:39Z","timestamp":1782981939709,"version":"3.54.5"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>To review the current literature for updates on pediatric nonsteroidal topical therapies (NSTT) for the treatment of atopic dermatitis (AD), psoriasis, alopecia areata (AA), vitiligo, and seborrheic dermatitis (SD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>The FDA approved difamilast and expanded the approved age ranges for roflumilast, tapinarof, and ruxolitinib to treat AD. Recent studies also show positive results with delgocitinib. In the field of psoriasis, current research shows promise for tapinarof and roflumilast in an expanded age range. Among new AA treatments, relevant literature supports the use of both ruxolitinib and tofacitinib. Research in pediatric vitiligo is currently focused on roflumilast and latanoprost. The FDA approved age ranges for roflumilast in SD treatment was expanded, and recent data shows promising efficacy and safety with long term use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Current pediatric topical therapies are limited for the treatment of AD, psoriasis, AA, vitiligo, and SD. Historically, first line treatment options have included topical corticosteroids (TCS), though these have an increased risk of side effects in a pediatric population. Future clinical practices will likely rely less on TCS and more on NSTT for treatments of chronic pediatric dermatologic conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000001580","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:00:32Z","timestamp":1780585232000},"page":"382-388","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Emerging topical nonsteroidal therapies in pediatric dermatology: atopic dermatitis, psoriasis, alopecia areata, vitiligo, and seborrheic dermatitis"],"prefix":"10.1097","volume":"38","author":[{"given":"Jordan","family":"Gillespie","sequence":"first","affiliation":[{"name":"Oregon Health & Science University, Departments of Dermatology and Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Funk","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Departments of Dermatology and Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dhossche","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Departments of Dermatology and Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Kenny","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Department of Pharmacy, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Small","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Departments of Dermatology and Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s44337-024-00021-x","article-title":"Optimized and safe use of topical corticosteroids in pediatric dermatology through interdisciplinary collaboration: a review","volume":"1","author":"Sreeraj","year":"2024","journal-title":"Discover Med"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2147\/PPA.S498527","article-title":"Predictors of topical corticosteroid adherence among caregivers of children with atopic eczema","volume":"19","author":"Liew","year":"2025","journal-title":"Patient Prefer Adherence"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.anai.2025.06.020","article-title":"New treatments in atopic dermatitis update","volume":"135","author":"Gallagher","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R8-20260702","doi-asserted-by":"crossref","first-page":"e15798","DOI":"10.1111\/ped.15798","article-title":"Posthoc safety\/efficacy analyses from pediatric delgocitinib atopic dermatitis trials","volume":"66","author":"Fukuie","year":"2024","journal-title":"Pediatr Int"},{"key":"R10-20260702","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s13555-025-01581-1","article-title":"A phase 3, long-term, open-label study of difamilast ointment to evaluate efficacy and safety in japanese infants with atopic dermatitis","volume":"16","author":"Saeki","year":"2026","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R11-20260702","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/pde.15840","article-title":"Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients aged 2-5\u200ayears with mild-to-moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial","volume":"42","author":"Eichenfield","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"R12-20260702","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaad.2025.05.1385","article-title":"Efficacy and safety of ruxolitinib cream in children aged 2 to 11\u200ayears with atopic dermatitis: results from TRuE-AD3, a phase 3, randomized double-blind study","volume":"93","author":"Eichenfield","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R13-20260702","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/1346-8138.17817","article-title":"Treatment satisfaction, efficacy, and safety of delgocitinib ointment for atopic dermatitis-induced rash on the face and neck: efficacy at reducing local side effects of topical Steroid and tacrolimus ointment","volume":"52","author":"Abe","year":"2025","journal-title":"J Dermatol"},{"key":"R14-20260702","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40257-025-00929-9","article-title":"Maximal usage trial of tapinarof cream 1% once daily in pediatric patients down to 2 years of age with extensive atopic dermatitis","volume":"26","author":"Paller","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"R15-20260702","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/1346-8138.17049","article-title":"Pediatric psoriasis: understanding pathological conditions and advances in treatment","volume":"51","author":"Morita","year":"2024","journal-title":"The Journal of dermatology"},{"key":"R16-20260702","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40272-023-00592-9","article-title":"Topical management of pediatric psoriasis: a review of new developments and existing therapies","volume":"26","author":"Lie","year":"2024","journal-title":"Paediatr Drugs"},{"key":"R17-20260702","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/pde.70013","article-title":"Early evidence of safety, clinical benefit, and pharmacokinetics of roflumilast cream 0.3% once daily for treatment of mild or moderate plaque psoriasis in children aged 2\u201311 years","volume":"43","author":"Hebert","year":"2026","journal-title":"Pediatr Dermatol"},{"key":"R19-20260702","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamadermatol.2025.1136","article-title":"Roflumilast foam, 0.3%, for psoriasis of the scalp and body: the ARRECTOR phase 3 randomized clinical trial","volume":"161","author":"Gooderham","year":"2025","journal-title":"JAMA Dermatol"},{"key":"R20-20260702","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40272-024-00620-2","article-title":"Treatment options for alopecia areata in children and adolescents","volume":"26","author":"Westerkam","year":"2024","journal-title":"Paediatr Drugs"},{"key":"R21-20260702","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R22-20260702","doi-asserted-by":"crossref","first-page":"624","DOI":"10.4103\/idoj.idoj_535_23","article-title":"Efficacy and safety of topical tofacitinib for the treatment of alopecia areata","volume":"15","author":"Chikhalkar","year":"2024","journal-title":"Indian Dermatol Online J"},{"key":"R23-20260702","doi-asserted-by":"crossref","first-page":"378","DOI":"10.36849\/JDD.7782","article-title":"Ruxolitinib 1.5% topical cream for the treatment of pediatric alopecia areata","volume":"23","author":"Tembunde","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"R24-20260702","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-025-00670-x","article-title":"Vitiligo","volume":"11","author":"Seneschal","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"R25-20260702","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamadermatol.2024.0021","article-title":"Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients","volume":"160","author":"Renert-Yuval","year":"2024","journal-title":"JAMA Dermatol"},{"key":"R26-20260702","first-page":"52","article-title":"Recalcitrant pediatric facial vitiligo successfully treated with roflumilast cream 0.3% once daily","volume":"18","author":"Warren","year":"2025","journal-title":"J Clin Aesthet Dermatol"},{"key":"R27-20260702","doi-asserted-by":"crossref","first-page":"e70549","DOI":"10.1111\/jocd.70549","article-title":"Topical latanoprost for eyelid vitiligo: effective repigmentation in two pediatric cases","volume":"24","author":"Liu","year":"2025","journal-title":"J Cosmet Dermatol"},{"key":"R28-20260702","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/10600280251355662","article-title":"Roflumilast and the changing landscape of seborrheic dermatitis treatment","volume":"60","author":"Dhillon","year":"2026","journal-title":"Ann Pharmacother"},{"issue":"(Suppl)","key":"R29-20260702","first-page":"24s","article-title":"Current understanding of seborrheic dermatitis: treatment options","volume":"29","author":"Turchin","year":"2025","journal-title":"J Cutan Med Surg"},{"key":"R30-20260702","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jaad.2023.12.065","article-title":"Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: a randomized, double-blinded, vehicle-controlled, phase 3 trial","volume":"90","author":"Blauvelt","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"R31-20260702","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40257-025-00984-2","article-title":"Long-term safety and efficacy of roflumilast foam 0.3% in patients with seborrheic dermatitis: a Phase II, open-label trial of up to 52 weeks","volume":"27","author":"Alexis","year":"2025","journal-title":"Am J Clin Dermatol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:00:29Z","timestamp":1782979229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001580","relation":{},"ISSN":["1531-698X"],"issn-type":[{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]}}}